Orphazyme's hour of reckoning approaches: "Its existence is threatened if it gets a clear no"
The US FDA will present its verdict on Orphazyme's drug candidate arimoclomol for treating NPC on June 17 at latest. According to an analyst and a former investor, the outcome is crucial to the Danish biotech firm.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN AND CATHERINE BRETT
Orphazyme's fate as a biotech company may be at stake when the US Food and Drug Administration (FDA) decides whether arimoclomol can be approved as a treatment for the rare metabolic disorder Niemann-Pick type C (NPC), says Danske Market's Senior Analyst Thomas Bowers.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
